Long-term effectiveness and safety of stereotactic gamma knife surgery as a primary sole treatment in the management of glomus jagulare tumor
•Glomus jugulare tumors are rare locally invasive skull base tumors.•Microsurgical treatment of glomus jagulare tumor entails high surgical risks.•GKS has established its role as adjuvant to microsurgery.•GKS as primary solely treatment is very efficient control of GJTs growth. This study aims to re...
Gespeichert in:
Veröffentlicht in: | Clinical neurology and neurosurgery 2018-05, Vol.168, p.34-37 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •Glomus jugulare tumors are rare locally invasive skull base tumors.•Microsurgical treatment of glomus jagulare tumor entails high surgical risks.•GKS has established its role as adjuvant to microsurgery.•GKS as primary solely treatment is very efficient control of GJTs growth.
This study aims to report and confirm long-term effectiveness and safety of stereotactic Gamma Knife Surgery as a primary sole treatment in the management of 40 glomus jagulare tumors patients.
Retrospective analysis of clinical and radiological outcomes of 40 GJTs consecutive patients treated with GKS as primary sole treatment at International Medical Center (IMC), Cairo-Egypt from the beginning of 2005 till the end of 2014,with mean follow-up period of 84 months (range 36–156 months), mean tumor volume was 6.5 cc, and mean peripheral radiation dose of 15 Gy, to mean isodose curve of 38%.
The most common neurological deficit at initial evaluation was bulbar symptoms in 24 patients, followed by pulsatile tinnitus in 22, deterioration of hearing in 20 patients. The overall clinical control achieved in 92.5% of patients, while actuarial tumor size control rate post- GKS was 97.5% at 3 years, 97% at 5 years and 92% at 10 years of follow-up period.
Gamma knife surgery could be used effectively and safely as a primary sole treatment tool in the management of glomus jugulare tumors. |
---|---|
ISSN: | 0303-8467 1872-6968 |
DOI: | 10.1016/j.clineuro.2018.02.037 |